Stockreport

Revolution Medicines Doubles Stock Offering Target to $2 Billion Following Pancreatic Cancer Breakthrough [TheStreet.com]

Revolution Medicines, Inc.  (RVMD) 
PDF Following this clinical success, the California biotech doubled its fundraising target, aiming for a $2 billion stock and debt offering to draw in new investors. On Mo [Read more]